Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial-Reference-Cited by-同舟云学术

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

Published:2013-04 Issue:4 Volume:13 Page:303-312
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bonnet Maryline,Bhatt Nilesh,Baudin Elisabeth,Silva Carlota,Michon Christophe,Taburet Anne-Marie,Ciaffi Laura,Sobry Agnès,Bastos Rui,Nunes Elizabete,Rouzioux Christine,Jani Ilesh,Calmy Alexandra

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference33 articles.

1. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach,2010

2. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin;Manosuthi;Clin Infect Dis,2006

3. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis;Cohen;J Antimicrob Chemother,2008

4. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa;Cohen;Antivir Ther,2009

5. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis;Gengiah;Eur J Clin Pharmacol,2012

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial;The Lancet HIV;2023-07

2. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database;British Journal of Clinical Pharmacology;2021-10-13

3. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial;The Lancet Infectious Diseases;2021-06

4. Raltegravir in patients with tuberculosis;The Lancet Infectious Diseases;2021-06

5. Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial;Wellcome Open Research;2021-01-11